吉西他滨灌注联合经尿道钬激光切除术对浅表性膀胱癌患者血清CXCL5及尿NMP22水平的影响

Effect of holmium laser resection of bladder tumors combined with gemcitabine bladder perfusion therapy on patients with superficial bladder cancer and its affection on levels of serum CXCL5 and value of urinary NMP 22

目的探究吉西他滨灌注联合经尿道钬激光切除术对浅表性膀胱癌患者血清趋化因子配体5(chemokine ligand-5,CXCL5)及尿核基质蛋白22(nuclear matrix protein 22,NMP 22)水平的影响。方法选取浅表性膀胱癌患者104例,根据随机数字表法分为对照组和观察组各52例。对照组给予尿道钬激光切除术治疗,观察组在对照组的基础上联合吉西他滨灌注治疗。比较2组术后复发率、平均复发时间、平均生存时间;治疗前后比较2组血管内皮生长因子(vascular endothelial growth factor,VEGF)、成纤维细胞生长因子(fibroblast growth factor,FGF)水平、CXCL5及尿NMP22水平。结果观察组术后1年和术后3年复发率低于对照组,平均复发时间和平均生存时间长于对照组,差异有统计学意义(P<0.05或P<0.01)。治疗后,2组血清VEGF、αFGF、βFGF、CXCL5和尿NMP22水平均低于治疗前,观察组血清VEGF、αFGF、βFGF、CXCL5和尿NMP22水平均低于对照组,差异有统计学意义(P<0.01)。结论吉西他滨灌注联合经尿道钬激光切除术治疗浅表性膀胱癌,能有效降低术后复发率,延长平均生存时间,显著降低血清CXCL5及尿NMP22水平。

Objective To analyze the effects of holmium laser resection of bladder tumors(HOLBT)combined with gemcitabine bladder perfusion therapy on patients with superficial bladder cancer and its affection on levels of serum CXCL5 and value of urinary NMP 22.Methods A total of 104 patients with csuperficial bladder cancer treated were selected as research objects,and divided into control group and observation group(52 cases in each group).Control group was given HOLBT,and observation group was treated with gemcitabine bladder perfusion therapy on the basis of control group.The postoperative recurrence,average recurrence time,average survival time and serum levels of growth factor,level of CXCL5 and NMP22 were compared between two groups.Results The postoperative recurrence within 1 year and 3 years and the average recurrence time and average survival time in control group after treatment were significantly higher than those in observation group,the difference was statistically significant(P<0.05 or P<0.01).The serum VEGF,aFGF,bFGF,CXCL5 and urinary NMP22 levels in observation group were significantly lower than those in control group.After treatment,the levels of VEGF,αFGF,βFGF,CXCL5 and NMP22 in the two groups were lower than those before treatment(P<0.01).Conclusion The HOLBT combined with gemcitabine bladder perfusion therapy on patients with superficial bladder cancer,can effectively reduce postoperative recurrence,prolong the mean survival time of patients,and can significantly reduce the level of CXCL5 and NMP22.